Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation

Cancer Research

Volumn 70, Issue 17, 2010, Pages 6697-6703

  Molina, Jennifer R ^a   Morales, Fabiana C ^a   Hayashi, Yuho ^a   Aldape, Kenneth D ^a   Georgescu, Maria Magdalena ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN NHEFR1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ONCOPROTEIN; PHOSPHOPROTEIN; PTEN PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR;

ARTICLE; ASTROCYTE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CYTOPLASM; ENZYME ACTIVATION; GENE OVEREXPRESSION; GLIOBLASTOMA; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MEMBRANE; CYTOPLASM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SODIUM-HYDROGEN ANTIPORTER;

EID: 77956288767     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1271     Document Type: Article

References (20)

1. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23: 2411-22. (Pubitemid 46218735)
2. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8. (Pubitemid 28268370)
3. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008;27: 6473-88.
4. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1998;8: 69-81.
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
6. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999;99:323-34.
7. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A 1999;96:10182-7. (Pubitemid 29422533)
8. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006;25:910-20.
9. von Stein W, Ramrath A, Grimm A, Muller-Borg M, Wodarz A. Direct association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals a link between the PAR/aPKC complex and phosphoinositide signaling. Development 2005;132:1675-86.
10. Wu X, Hepner K, Castelino-Prabhu S, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A 2000;97:4233-8. (Pubitemid 30226116)
11. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-9.
12. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
13. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/ CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
14. Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME. NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia 2009;11:377-87.
15. Morales FC, Molina JR, Hayashi Y, Georgescu MM. Overexpresssion of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol 2010;12:528-39.
16. Kreimann EL, Morales FC, de Orbeta-Cruz J, et al. Cortical stabilization of β-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 2007;26:5290-9.
17. Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Curr Mol Med 2008;8:459-68.
18. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A 2009;106:480-5.
19. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 2004;23:8681-7.
20. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. EBP50, a β-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 2003;38:178-86. (Pubitemid 36775809)